



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



AGN 193109 (sodium salt)

Item No. 23975

Formal Name: 4-[2-[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]-benzoic acid, monosodium salt
Synonym: CD3106
MF: C₂₈H₂₃O₂ • Na
FW: 414.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AGN 193109 (sodium salt) is supplied as a solid. A stock solution may be made by dissolving the AGN 193109 (sodium salt) in the solvent of choice. AGN 193109 (sodium salt) is slightly soluble in organic solvents such as DMSO and methanol, which should be purged with an inert gas.

Description

AGN 193109 is a potent antagonist of retinoic acid receptors (RARs; $K_d = 2, 2, \text{ and } 3 \text{ nM}$ for RAR α , β , and γ , respectively).¹ It is selective for RARs over retinoid X receptors (RXRs; $K_d = >10,000 \text{ nM}$ for human RXR α , β , and γ receptors). AGN 193109 reverses changes in cell morphology induced by the RAR agonist TTNPB (Item No. 16144) in ECE16-1 human endometrial ectocervical epithelial cells. It also reverses the growth suppressive effects of all-*trans*-RA, 13-*cis*-RA, and 9-*cis*-RA (Item No. 14587) when used at a 10-fold molar excess. AGN 193109 decreases expression of cytokeratin K5-8, 13, 14, 16, 17, and 19 genes, markers of retinoid action in ECE16-1 cells, when co-administered with TTNPB but not when used alone. *In vivo*, AGN 193109 induces cleft palate or frontonasal dysplasia and eye malformations in fetuses of pregnant mice following a single oral dose of 1 mg/kg.²

References

1. Agarwal, C., Chandraratna, A.S., Johnson, A.L., *et al.* AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells. *J. Biol. Chem.* **271(21)**, 12209-12212 (1996).
2. Kochhar, D.M., Jiang, H., Penner, J.D., *et al.* The use of a retinoid receptor antagonist in a new model to study vitamin A-dependent developmental events. *Int. J. Dev. Biol.* **42(4)**, 601-608 (1998).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM